Cipher Pharmaceuticals (OTCMKTS:CPHRF – Get Free Report) (TSE:CPH) is projected to post its resultson Thursday, November 5th. Analysts expect Cipher Pharmaceuticals to post earnings of $0.1989 per share and revenue of $12.23 million for the quarter.
Cipher Pharmaceuticals Trading Up 1.2%
Shares of Cipher Pharmaceuticals stock opened at $9.41 on Tuesday. The firm has a fifty day moving average of $9.93 and a two-hundred day moving average of $11.39. Cipher Pharmaceuticals has a 52 week low of $8.92 and a 52 week high of $15.00.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a Canadian specialty pharmaceutical company focused primarily on developing, acquiring, and commercializing medicines for dermatology and other areas with unmet medical needs. The company’s business model emphasizes licensing and advancing differentiated prescription products rather than maintaining a broad, traditional drug-discovery operation.
Cipher’s dermatology portfolio has included Epuris, an oral isotretinoin product used to treat severe acne, as well as products for conditions such as actinic keratosis and excessive facial hair.
Read More
- Five stocks we like better than Cipher Pharmaceuticals
- SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
